Key result
Ablation of HSPA12A in mice promoted cardiac fibroblast activation and cardiac fibrosis following myocardial infarction, whereas its overexpression inhibited activation through glycolysis inhibition.
Why the study?
Cardiac fibrosis drives adverse remodeling and functional decline in heart disease, but no ideal approach for controlling cardiac fibroblast activation currently exists.
HSPA12A is a novel endogenous inhibitor of cardiac fibroblast activation and cardiac fibrosis, acting via the USP10/p53/glycolysis pathway.
Answers are grounded in this paper and cite their sources.
HSPA12A may represent an antifibrotic target in post-MI remodeling; leaves open clinical translation pending human validation.
INTRODUCTION: Cardiac fibrosis is the main driver for adverse remodeling and progressive functional decline in nearly all types of heart disease including myocardial infarction (MI). The activation of cardiac fibroblasts (CF) into myofibroblasts is responsible for cardiac fibrosis. Unfortunately, no ideal approach for controlling CF activation currently exists. OBJECTIVES: This study investigated the role of Heat shock protein A12A (HSPA12A), an atypical member of the HSP70 family, in CF activation and MI-induced cardiac fibrosis. METHODS: Primary CF and Hspa12a knockout mice were used in the experiments. CF activation was indicated by the upregulation of myofibroblast characters including alpha-Smooth muscle actin (αSMA), Collagen, and Fibronectin. Cardiac fibrosis was illustrated by Masson's trichrome and picrosirius staining. Cardiac function was examined using echocardiography. Glycolytic activity was indicated by levels of extracellular lactate and the related protein expression. Protein stability was examined following cycloheximide and MG132 treatment. Protein-protein interaction was examined by immunoprecipitation-immunoblotting analysis. RESULTS: HSPA12A displayed a high expression level in quiescent CF but showed a decreased expression in activated CF, while ablation of HSPA12A in mice promoted CF activation and cardiac fibrosis following MI. HSPA12A overexpression inhibited the activation of primary CF through inhibiting glycolysis, while HSPA12A knockdown showed the opposite effects. Moreover, HSPA12A upregulated the protein expression of transcription factor p53, by which mediated the HSPA12A-induced inhibition of glycolysis and CF activation. Mechanistically, this action of HSPA12A was achieved by acting as a scaffolding protein to bind p53 and ubiquitin specific protease 10 (USP10), thereby promoting the USP10-mediated p53 protein stability and the p53-medicated glycolysis inhibition. CONCLUSION: The present study provided clear evidence that HSPA12A is a novel endogenous inhibitor of CF activation and cardiac fibrosis. Targeting HSPA12A in CF could represent a promising strategy for the management of cardiac fibrosis in patients.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2024) studied Cardiac fibrosis and myocardial infarction. HSPA12A ablation or overexpression vs. Wild-type or control was evaluated on Cardiac fibroblast activation and cardiac fibrosis. Ablation of HSPA12A in mice promoted cardiac fibroblast activation and cardiac fibrosis following myocardial infarction, whereas its overexpression inhibited activation through glycolysis inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: